Upgrade to SI Premium - Free Trial

Today's FDA news a 'clear negative' for Hims and Hers (HIMS) - BofA Securities

February 21, 2025 10:29 AM
BofA Securities analyst Michael Cherny reiterated an Underperform rating and $21.00 price target on Hims and Hers (NYSE: HIMS) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles